Author

admin

Browsing

The U.S. and Iran resumed nuclear negotiations on Friday in Rome as differences over demands have spilled over into the public sphere, making the red lines for both parties increasingly clear. 

Iranian Supreme Leader Ayatollah Ali Khamenei this week criticized Washington’s position that has called for an apparent ban on all uranium enrichment in Iran and suggested a deal may not be possible.

The White House did not answer Fox News Digital’s questions about whether it is in fact calling for a ban on uranium enrichment for civil needs like nuclear energy, but on Friday Iranian Foreign Ministry spokesman Esmaeil Baghaei told reporters that ‘This round of talks is especially sensitive.’

According to Iranian media outlets, Tehran’s Foreign Minister Abbas Araghchi left the negotiations and said, ‘I hope that in the next one or two meetings we can reach solutions that will allow the negotiations to progress. 

‘With Oman’s solutions to remove obstacles, there is a possibility of progress,’ though he did not expand on what the hiccups were or what Oman’s solutions may have been.

Araghchi, who was set to negotiate largely indirectly with Middle East envoy Steve Witkoff through Omani mediators, made Tehran’s position on Washington’s apparent demands clear in a post to X early on Friday. 

‘Figuring out the path to a deal is not rocket science,’ he said. ‘Zero nuclear weapons = we DO have a deal. Zero enrichment = we do NOT have a deal. 

‘Time to decide,’ he added.

Iran has claimed it has no intention of building a nuclear weapon. But steps Tehran has taken, like bolstering its missile program, which could give it the technology to launch a nuclear warhead, and stockpiling enough near-weapons-grade enriched uranium to possess five nuclear weapons, have experts worried, including the U.N.’s International Atomic Energy Agency. 

While uranium enrichment for nuclear energy is a power source many countries, including the U.S., rely on for their energy needs, Iran’s nuclear energy amounts to less than 1% of its energy consumption. 

Secretary of State Marco Rubio said on Tuesday that the U.S. is attempting to form a deal that would enable Iran to have a civil nuclear energy program that does not include enriched uranium, though he admitted that this ‘will not be easy’.

‘Washington’s insistence on zero enrichment, I think, is the only sober, sane, non-proliferation approach you can take [with] the Islamic Republic of Iran, which has not stopped enriching uranium at various levels since April 2006 when this entire crisis really was kicked off, Behnam Ben Taleblu, Iran expert and senior fellow with the Foundation for Defense of Democracies told Fox News Digital.

‘Iran has more to lose by pushing away from the table,’ he continued. ‘Iran is engaging in 2025 for a very different reason than 2013 and 2015. It’s trying to blunt maximum pressure. It’s trying to prevent an Israeli military attack, and it’s trying to prevent European snap-back [sanctions]. 

‘This is why Iran is engaging today, and the Trump administration needs to be cognizant that, because of that, it does have the leverage in these negotiations and can demand more,’ Ben Taleblu urged. 

This post appeared first on FOX NEWS

Hundreds of Ukrainian prisoners were released Friday in an exchange with Russia, Ukrainian President Volodymyr Zelenskyy announced, adding that ‘It is very important to return everyone who remains in captivity. 

‘We are bringing our people home. The first stage of the ‘1000-for-1000’ exchange agreement has been carried out. This agreement was reached during the meeting in Turkey, and it is crucial to implement it in full,’ Zelenskyy wrote on X, referencing a recent deal between Russian and Ukrainian officials.

‘Today — 390 people. On Saturday and Sunday, we expect the exchange to continue. Thank you to everyone who is helping and working 24/7 to bring Ukrainian men and women back home. It is very important to return everyone who remains in captivity. We are verifying every surname, every detail about each person. We will continue our diplomatic efforts to make such steps possible,’ he added.

The swap unfolded at the border between Belarus and Ukraine, a senior Ukrainian official told the Associated Press. Moscow had no immediate comment. On his X account, Zelenskyy released images purportedly showing the newly-freed Ukrainians.

‘A major prisoners swap was just completed between Russia and Ukraine. It will go into effect shortly,’ Trump wrote on Truth Social this morning. ‘Congratulations to both sides on this negotiation. This could lead to something big???’ 

On Thursday, Ukrainian President Volodymyr Zelenskyy wrote on X that ‘I held a meeting on the preparation for an exchange’ and ‘The agreement to release 1,000 of our people from Russian captivity was perhaps the only tangible result of the meeting in Turkey.’ 

Trump had a phone call with Russian President Vladimir Putin on Monday. Following the conversation, Trump said ‘I believe it went very well.’ 

‘Russia and Ukraine will immediately start negotiations toward a Ceasefire and, more importantly, an END to the War. The conditions for that will be negotiated between the two parties, as it can only be, because they know details of a negotiation that nobody else would be aware of,’ Trump said. ‘The tone and spirit of the conversation were excellent. If it wasn’t, I would say so now, rather than later.’ 

Putin, in a statement after the call, also noted that ‘a ceasefire with Ukraine is possible’ but noted that ‘Russia and Ukraine must find compromises that suit both sides.’ 

The Kremlin then said Thursday that both sides had no direct peace talks scheduled. 

‘There is no concrete agreement about the next meetings,’ Kremlin spokesman Dmitry Peskov said, according to the Associated Press. ‘They are yet to be agreed upon.’ 

Fox News Digital’s Morgan Phillips contributed to this report. 

This post appeared first on FOX NEWS

Rio Tinto (ASX:RIO,NYSE:RIO,LSE:RIO)said on Monday (May 19) that it has signed binding agreements with Corporación Nacional Del Cobre de Chile (Codelco) to develop and operate a high-grade lithium project.

The asset is located in the Salar de Maricunga, a large lithium-containing resource base in Atacama, Chile. Its brine is said to have one of the highest average grades of lithium content in the world.

According to Rio Tinto, it will acquire a 49.99 percent interest in the company Salar de Maricunga, through which Codelco holds its licenses and mining concessions related to the resource base.

Codelco is a state-owned firm formed in 1976. Its full name translates to “National Copper Corporation of Chile.”

“We are honoured to be chosen as Codelco’s partner to deliver a world-class project using Direct Lithium Extraction technology in the Salar de Maricunga, leveraging our expertise as a leading producer of lithium for the global market,” said Rio Tinto Chief Executive Jakob Stausholm. “Developing this significant lithium resource will deliver further value-adding growth in our portfolio of critical minerals essential for the energy transition.”

In 2023, Rio and Codelco entered a joint venture for the exploration of Nuevo Cobre, situated within the Potrerillos mining district, also in Atacama. Codelco owns about 43 percent of Nuevo Cobre, while Rio Tinto owns about 58 percent.

For the Salar de Maricunga partnership, Rio will invest AU$350 million in initial funding for additional studies and resource analysis that will assist in creating a final investment decision.

Once a decision is made, AU$500 million will be dedicated toward construction costs. Another AU$50 million will be allocated should the venture deliver its first lithium target by the end of 2030.

The new partnership with Codelco forms part of Rio Tinto’s long-term lithium plan, which includes a production goal of over 200,000 metric tons of lithium carbonate equivalent annually by 2028.

The company recently completed its acquisition of Arcadium Lithium, making it the world’s third top lithium producer.

Subject to regulatory approvals and the satisfaction of customary conditions, the Salar de Maricunga transaction is expected to close by the end of the first quarter of 2026.

Securities Disclosure: I, Gabrielle de la Cruz, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Group Eleven Resources Corp. (TSXV: ZNG) (OTCQB: GRLVF) (FSE: 3GE) (‘Group Eleven’ or the ‘Company’) is pleased to announce that its common shares have been approved for uplisting from the OTCBB to the OTCQB Venture Market, effective today. The Company will continue to trade under the symbol ‘GRLVF’ on the OTC and will continue to trade under the symbol ‘ZNG’ on the TSXV market.

The OTCQB is a premier marketplace for early-stage and developing companies, offering increased visibility and credibility among U.S. investors. This uplisting reflects Group Eleven’s commitment to transparency, improved liquidity, and adherence to high financial reporting standards.

‘We are thrilled to achieve this milestone as we transition to the OTCQB market,’ said Bart Jaworski, CEO. ‘This uplisting enhances our ability to attract a broader investor base and supports our ongoing efforts to advance our Ballywire zinc-lead-silver and copper discovery in the Republic of Ireland. Our decision to be added to the OTC Markets Blue Sky Report will also help in boosting our visibility in the United States.’

Trading the Company’s shares on the OTCQB Market provides the Company with a dealer market in the United States that will provide easier access for US based investors and shareholders. The OTCQB Market through its SEC registered OTC Link ATS features over 110 US broker-dealers. The Company has also applied for Depository Trust Company (DTC) eligibility. DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies.

About Group Eleven Resources

Group Eleven Resources Corp. (TSXV: ZNG) (OTCQB: GRLVF) (FSE: 3GE) is drilling the most significant mineral discovery in the Republic of Ireland in over a decade. The Company announced the Ballywire discovery in September 2022, demonstrating high grades of zinc, lead, silver, copper, germanium and locally, antimony. Ballywire is located 20km from Company’s 77.64%-owned Stonepark zinc-lead deposit1, which itself is located adjacent to Glencore’s Pallas Green zinc-lead deposit2. The Company’s two largest shareholders are Glencore Canada Corp. (16.1% interest) and Michael Gentile (16.0%). Additional information about the Company is available at www.groupelevenresources.com.

ON BEHALF OF THE BOARD OF DIRECTORS
Bart Jaworski, P.Geo.
Chief Executive Officer

E: b.jaworski@groupelevenresources.com | T: +353-85-833-2463
E: j.webb@groupelevenresources.com | T: 604-644-9514

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Information

This press release contains forward-looking statements within the meaning of applicable securities legislation. Such statements include, without limitation, statements regarding the continuation of trading of the Company’s shares on the TSXV and OTCQB and the impact the uplisting will have on the Company’s performance. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking statements as a result of various factors, including, but not limited to, general market, economic or business conditions. All of the Company’s public disclosure filings may be accessed via www.sedarplus.ca and readers are urged to review these materials, including the technical reports filed with respect to the Company’s mineral properties.

_________________________
1 Stonepark MRE is 5.1 million tonnes of 11.3% Zn+Pb (8.7% Zn and 2.6% Pb), Inferred (Apr-17-2018)
2 Pallas Green MRE is 45.4 million tonnes of 8.4% Zn+Pb (7.2% Zn + 1.2% Pb), Inferred (Glencore, Dec-31-2024)

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253170

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

‘Not for distribution to United States newswire services or for dissemination in the United States.’

Forte Minerals Corp . ( ‘ Forte ‘ or the ‘ Company ‘ ) ( CSE: CUAU ) ( OTCQB: FOMNF ) ( Frankfurt: 2OA ), intends to complete a non-brokered private placement (the ‘Offering’) to raise up to C$2,400,000 for drilling and exploration programs on the Company’s Peruvian projects and for general working capital, all as further outlined below.

The Offering involves the sale of up to 6,000,000 units (each a ‘Unit’) at a price of $0.40 per Unit.

Unit Terms:

  • Each Unit: one common share and one-half of one common share purchase warrant
  • Warrant: each whole warrant exercisable for one common share at C$0.60 until the date that is 24 months from the closing of the Offering, provided the warrants are subject to accelerated exercise such that if the closing price of the Company’s common shares exceeds C$0.90 per share for a period of 20 consecutive trading days, the Company may give notice of the acceleration of the warrants’ term to a period of 30 days following such notice.

All securities issued will be subject to a statutory four-month-plus-one-day hold period in accordance with applicable Canadian securities laws. Additional restrictions may apply pursuant to the Securities Act of 1933, as amended, to U.S. investors, if any.

Use of Proceeds:

  • Pucarini: Inaugural five-hole drill program for total of 1750m scheduled to start this July 2025.
  • Esperanza : MT Survey
  • Alto Ruri : DIA Drill Permitting and Community Agreements, surface exploration work including follow-up alteration and geological mapping, geochemical sampling, spectral analysis, IP and CSMAT.
  • General working capital

Finder’s fees may be paid to eligible persons in connection with the Offering, subject to the policies of the CSE.

The Company, at its discretion, reserves the right to increase the size of the Offering by up to $300,000.00 through the sale of 750,000 additional Units, for an aggregate Offering not exceeding $2,700,000.

We appreciate our shareholders’ continued confidence,’ stated Patrick Elliott, President and CE O. ‘This financing positions us to drill test a high sulphidation system that’s never been drilled and to unlock the value of Alto Ruri, Esperanza and Miscanthus .’

The Offering is expected to close on or before June 15, 2025, subject to customary conditions, including the receipt of all required regulatory approvals .

ABOUT Forte Minerals CORP.

Forte Minerals Corp. is an exploration company with a strong portfolio of high-quality copper (‘ Cu ‘) and gold (‘ Au ‘) assets in Perú. Our strategic partnership with GlobeTrotters Resources Perú S.A.C. (‘ GTR ‘) grants us access to a comprehensive project pipeline, enabling us to target the most promising opportunities. This collaboration focuses on historically discovered, drill-ready targets, driving significant value in Cu and Au resource development.

On behalf of  Forte Minerals CORP.
(signed) ‘ Patrick Elliott’
Chief Executive Officer

For further information, please contact:
Forte Minerals Corp.
office: (604) 983-8847
info@forteminerals.co m
www.forteminerals.com

Certain statements included in this press release constitute forward-looking information or statements (collectively, ‘forward-looking statements’), including those identified by the expressions ‘anticipate’, ‘believe’, ‘plan’, ‘estimate’, ‘expect’, ‘intend’, ‘may’, ‘should’ and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the company with respect to the matter described in this new release. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and risks and uncertainties is contained under ‘Risk Factors and Uncertainties’ in the Company’s latest management’s discussion and analysis, which is available under the Company’s SEDAR+ profile at www.sedarplus.ca, and in other filings that the Company has made and may make with applicable securities authorities in the future.

Forward-looking statements are not a guarantee of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include the continued availability of capital and financing, and general economic, market or business conditions. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the statements will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements.

Neither the Canadian Securities Exchange (the ‘CSE’) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

News Provided by GlobeNewswire via QuoteMedia

This post appeared first on investingnews.com

Here’s a quick recap of the crypto landscape for Wednesday (May 21) as of 9:00 p.m. UTC.

Get the latest insights on Bitcoin, Ethereum and altcoins, along with a round-up of key cryptocurrency market news.

Bitcoin and Ethereum price update

Bitcoin (BTC) was priced at US$108,452 as markets closed, up 1.5 percent in 24 hours. The day’s range for the cryptocurrency brought a low of US$106,490 and a new all-time high of US$109,400.

Bitcoin performance, May 21, 2025.

Chart via TradingView.

Bitcoin surpassed its previous record of US$109,228, set on January 20. Following this peak, the price quickly declined to approximately US$106,000 within an hour, but subsequently stabilized around US$107,000.

Ethereum (ETH) finished the trading day at US$2,507.94, a 0.5 percent increase over the past 24 hours. The cryptocurrency reached an intraday low of US$2,473.89 and saw a daily high of US$2,597.51.

Altcoin price update

  • Solana (SOL) closed at US$170.94, up 2 percent over 24 hours. SOL experienced a low of US$167.29 and a high of US$174.24.
  • XRP is trading at US$2.39, reflecting a 0.5 percent increase over 24 hours. The cryptocurrency reached a daily low of US$2.35 and a high of US$2.42.
  • Sui (SUI) is priced at US$3.91, showing an increaseof 0.9 percent over the past 24 hours. It achieved a daily low of US$3.86 and a high of US$4.04.
  • Cardano (ADA) is trading at US$0.7606, up 3 percent over the past 24 hours. Its lowest price of the day was US$0.7487, and it reached a high of US$0.7797.

Today’s crypto news to know

US$300,000 Bitcoin bet gains attention, but remains a long shot

A bold options trade is betting Bitcoin could hit US$300,000 by the end of June.

According to market data, call options at that stratospheric strike price were the second most traded on Deribit on Tuesday (May 20), hinting at a mix of speculative enthusiasm and hedging behavior among traders.

While some analysts remain optimistic — Standard Chartered (LSE:STAN,OTC Pink:SCBFF), for instance, sees Bitcoin possibly reaching US$120,000 by Q2 — no major forecast comes close to US$300,000.

On Tuesday, Bitcoin hovered near US$107,000, not far from its record high of US$109,241 in January.

Still, market experts caution that without a strong catalyst, the current rally may not sustain its upward trajectory. Betting markets like Polymarket place only a 9 percent chance of Bitcoin hitting even US$250,000 this year, underscoring how isolated this US$300,000 wager truly is.

Bitget becomes world’s third top crypto exchange by trading volume

Bitget has officially surged into third place among global crypto exchanges, reporting US$757.6 billion in futures trading volume and US$68.6 billion in spot volume for April of this year.

The Seychelles-based platform has made a name for itself through features like copy trading, which allows users to mimic high-performing traders in real time. Bitget’s April performance stood out despite a broader market correction, expanding its market share to 7.2 percent and pushing its user base above 120 million. The exchange’s rise signals increasing demand for advanced crypto trading products beyond the traditional buy-and-hold strategy.

CME’s XRP futures launch with US$19 million volume

XRP joined the roster of cryptocurrencies traded on CME Group’s (NASDAQ:CME) derivatives exchange as the firm launched futures contracts that pulled in over US$19 million in notional volume on Sunday (May 18).

The first day’s tally easily eclipsed Solana’s March debut of US$12.3 million, putting XRP alongside BTC, ETH and SOL in CME’s crypto futures lineup. Offered in both micro (2,500 XRP) and standard (50,000 XRP) sizes, the cash-settled contracts allow investors to speculate on XRP’s price without owning the token.

The timing is noteworthy, as the US Securities and Exchange Commission (SEC) continues to drag its feet on pending exchange-traded fund applications for XRP and SOL, leaving futures as the most viable institutional gateway.

XRP futures could see broader uptake if regulatory clarity around token classification progresses. The SEC’s recent legal moves against other issuers may also increase demand for regulated products like these.

Crypto.com and Kraken secure MiFID licenses for European expansion

Crypto.com and Kraken have both secured Markets in Financial Instruments Directive (MiFID) licenses to offer crypto derivatives in Europe. Crypto.com secured its license through the acquisition of A.N. Allnew Investments, a Cyprus-based financial firm. Kraken acquired an unnamed Cypriot investment firm to gain its MiFID license.

A MiFID license allows entities to offer crypto derivatives in the EU. Platforms must meet strict regulations, enabling them to provide complex crypto financial products to more European investors under harmonized EU rules.

The moves underscore the increasing maturity of the cryptocurrency market and the proactive steps exchanges are taking to operate within established legal and financial frameworks in key global jurisdictions.

SEC accuses Unicoin of US$100 million fraud

The SEC has charged crypto firm Unicoin and four top executives with running what it calls a US$100 million securities fraud scheme, alleging the company lied about its assets and sales performance.

According to the complaint, Unicoin misled investors by falsely claiming to own prime real estate in locations like Thailand and Argentina, inflating the value of these assets by over US$1 billion. The company also allegedly exaggerated the sales of its ‘rights certificates,’ stating it had raised US$3 billion when the real figure was just US$110 million.

The SEC is seeking disgorgement and civil penalties, and notes that Unicoin rejected a prior attempt to settle the matter.

CEO Alexander Konanykhin told investors last month that the company had “declined to show up” for an SEC settlement meeting, labeling it an “ultimatum.”

Robinhood proposes tokenized RWA framework

Robinhood Markets (NASDAQ:HOOD) has proposed a 42 page framework to the SEC for national regulation of tokenized real-world assets (RWAs), as reported by Forbes on Tuesday.

The proposal also outlines the creation of the Real World Asset Exchange (RRE), a trading platform that would offer off-chain trade matching and on-chain settlement. To ensure efficiency, transparency and global compliance, the RRE would integrate KYC and AML tools through partnerships with Jumio and Chainalysis.

A central aspect of Robinhood’s proposal is the concept of token-asset equivalence. This would classify tokens representing assets like US Treasury bonds as the underlying asset itself, rather than a derivative.

This approach aims to enable institutions and broker-dealers to manage tokenized RWAs within the current regulatory structure, potentially simplifying custody, trading and settlement procedures.

New Bitcoin accumulation metric

As enterprises continue to build BTC holdings, a new analytical metric, days to cover mNAV, is being used to estimate how long it would take a company to acquire enough BTC to match its market capitalization.

The calculation uses the company’s current multiple of net asset value (mNAV) and its daily BTC yield, incorporating compounding to provide a forward-looking, growth-adjusted valuation.

The formula is: Days to Cover = ln(mNAV) / ln(1 + BTC Yield)

Data from significant Bitcoin-acquiring companies like Strategy (NASDAQ:MSTR), Metaplanet (TSE:3350,OTCQX:MTPLF) and Semler Scientific (NASDAQ:SMLR) between October 2024 and May 2025 indicates an increasingly efficient market that facilitates Bitcoin accumulation for large entities.

The formula was proposed by Adam Back on May 9, and gained traction after being reposted by X user @ActuallyClimber on May 14. CoinDesk reported on its increasing adoption within crypto circles on Wednesday.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

It took six months, countless hours on hold and intervention from state regulators before Sue Cover says she finally resolved an over $1,000 billing dispute with UnitedHealthcare in 2023.

Cover, 46, said she was overbilled for emergency room visits for her and her son, along with a standard ultrasound. While Cover said her family would eventually have been able to pay the sum, she said it would have been a financial strain on them.

Cover, a San Diego benefits advocate, said she had conversations with UnitedHealthcare that “felt like a circular dance.” Cover said she picked through dense policy language and fielded frequent calls from creditors. She said the experience felt designed to exhaust patients into submission.

“It sometimes took my entire day of just sitting on the phone, being on hold with the hospital or the insurance company,” Cover said.

Cover’s experience is familiar to many Americans. And it embodies rising public furor toward insurers and in particular UnitedHealthcare, the largest private health insurer in the U.S., which has become the poster child for problems with the U.S. insurance industry and the nation’s sprawling health-care system.

The company and other insurers have faced backlash from patients who say they were denied necessary care, providers who say they are buried in red tape and lawmakers who say they are alarmed by its vast influence.

UnitedHealthcare in a statement said it is working with Cover’s provider to “understand the facts of these claims.” The company said it is “unfortunate that CNBC rushed to publish this story without allowing us and the provider adequate time to review.” CNBC provided the company several days to review Cover’s situation before publication.

Andrew Witty, CEO of UnitedHealthcare’s company, UnitedHealth Group, stepped down earlier this month for what the company called “personal reasons.” Witty had led the company through the thick of public and investor blowback. The insurer also pulled its 2025 earnings guidance this month, partly due to rising medical costs, it said.

UnitedHealth Group is by far the biggest company in the insurance industry by market cap, worth nearly $275 billion. It controls an estimated 15% of the U.S. health insurance market, serving more than 29 million Americans, according to a 2024 report from the American Medical Association. Meanwhile, competitors Elevance Health and CVS Health control an estimated 12% of the market each.

It’s no surprise that a company with such a wide reach faces public blowback. But the personal and financial sensitivity of health care makes the venom directed at UnitedHealth unique, some experts told CNBC.

Shares of UnitedHealth Group are down about 40% this year following a string of setbacks for the company, despite a temporary reprieve sparked in part by share purchases by company insiders. In the last month alone, UnitedHealth Group has lost nearly $300 billion of its $600 billion market cap following Witty’s exit, the company’s rough first-quarter earnings and a reported criminal probe into possible Medicare fraud.

In a statement about the investigation, UnitedHealth Group said, “We stand by the integrity of our Medicare Advantage program.”

Over the years, UnitedHealthcare and other insurers have also faced numerous patient and shareholder lawsuits and several other government investigations.

UnitedHealth Group is also contending with the fallout from a February 2024 ransomware attack on Change Healthcare, a subsidiary that processes a significant portion of the country’s medical claims.

More recently, UnitedHealthcare became a symbol for outrage toward insurers following the fatal shooting of its CEO, Brian Thompson, in December. Thompson’s death reignited calls to reform what many advocates and lawmakers say is an opaque industry that puts profits above patients.

The problems go deeper than UnitedHealth Group: Insurers are just one piece of what some experts call a broken U.S. health-care system, where many stakeholders, including drugmakers and pharmacy benefit managers, are trying to balance patient care with making money. Still, experts emphasized that insurers’ cost-cutting tactics — from denying claims to charging higher premiums — can delay or block crucial treatment, leave patients with unexpected bills, they say, or in some cases, even mean the difference between life and death.

In a statement, UnitedHealthcare said it is unfortunate that CNBC appears to be drawing broad conclusions based on a small number of anecdotes.”

Frustration with insurers is a symptom of a broader problem: a convoluted health-care system that costs the U.S. more than $4 trillion annually.

U.S. patients spend far more on health care than people anywhere else in the world, yet have the lowest life expectancy among large, wealthy countries, according to the Commonwealth Fund, an independent research group. Over the past five years, U.S. spending on insurance premiums, out-of-pocket co-payments, pharmaceuticals and hospital services has also increased, government data show.

While many developed countries have significant control over costs because they provide universal coverage, the U.S. relies on a patchwork of public and private insurance, often using profit-driven middlemen to manage care, said Howard Lapin, adjunct professor at the University of Illinois Chicago School of Law.

But the biggest driver of U.S. health spending isn’t how much patients use care — it’s prices, said Richard Hirth, professor of health management and policy at the University of Michigan.

There is “unbelievable inflation of the prices that are being charged primarily by hospitals, but also drug companies and other providers in the system,” said Sabrina Corlette, co-director of the Center on Health Insurance Reforms at Georgetown University.

Lapin said factors such as overtreatment, fraud, health-care consolidation and administrative overhead raise costs for payers and providers, who then pass those on through higher prices. U.S. prescription drug prices are also two to three times higher than those in other developed countries, partly due to limited price regulation and pharmaceutical industry practices such as patent extensions.

While patients often blame insurers, the companies are only part of the problem. Some experts argue that eliminating their profits wouldn’t drastically lower U.S. health-care costs.

Still, UnitedHealthcare and other insurers have become easy targets for patient frustration — and not without reason, according to industry experts.

Their for-profit business model centers on managing claims to limit payouts, while complying with regulations and keeping customers content. That often means denying services deemed medically unnecessary, experts said. But at times, insurers reject care that patients need, leaving them without vital treatment or saddled with hefty bills, they added.

Insurers use tools such as deductibles, co-pays, and prior authorization — or requiring approval before certain treatments — to control costs. Industry experts say companies are increasingly relying on artificial intelligence to review claims, and that can sometimes lead to inaccurate denials.

“It’s all part of the same business model — to avoid paying as many claims as possible in a timely fashion,” said Dylan Roby, an affiliate at the UCLA Center for Health Policy Research.

While other private U.S. insurers employ many of the same tactics, UnitedHealth Group appears to have faced the most public backlash due to its size and visibility.

UnitedHealth Group’s market value dwarfs the sub-$100 billion market caps of competitors such as CVS, Cigna and Elevance. UnitedHealth Group booked more than $400 billion in revenue in 2024 alone, up from roughly $100 billion in 2012.

It has expanded into many parts of the health-care system, sparking more criticism of other segments of its business — and the company’s ability to use one unit to benefit another.

UnitedHealth Group grew by buying smaller companies and building them into its growing health-care business. The company now serves nearly 150 million people and controls everything from insurance and medical services to sensitive health-care data.

UnitedHealth Group owns a powerful pharmacy benefit manager, or PBM, called Optum Rx, which gives it even more sway over the market.

PBMs act as middlemen, negotiating drug rebates on behalf of insurers, managing lists of drugs covered by health plans and reimbursing pharmacies for prescriptions. But lawmakers and drugmakers accuse them of overcharging plans, underpaying pharmacies and failing to pass savings on to patients.

Owning a PBM gives UnitedHealth Group control over both supply and demand, Corlette said. Its insurance arm influences what care is covered, while Optum Rx determines what drugs are offered and at what price. UnitedHealth Group can maximize profits by steering patients to lower-cost or higher-margin treatments and keeping rebates, she said.

The company’s reach goes even further, Corlette added: Optum Health now employs or affiliates with about 90,000 doctors — nearly 10% of U.S. physicians — allowing UnitedHealth Group to direct patients to its own providers and essentially pay itself for care.

A STAT investigation last year found that UnitedHealth uses its physicians to squeeze profits from patients. But the company in response said its “providers and partners make independent clinical decisions, and we expect them to diagnose and document patient information completely and accurately in compliance with [federal] guidelines.”

Other insurers, such as CVS and Cigna, also own large PBMs and offer care services. But UnitedHealth Group has achieved greater scale and stronger financial returns.

“I think the company is certainly best in class when it comes to insurers, in terms of providing profits for shareholders,” said Roby. “But people on the consumer side probably say otherwise when it comes to their experience.”

No one knows exactly how often private insurers deny claims, since they aren’t generally required to report that data. But some analyses suggest that UnitedHealthcare has rejected care at higher rates than its peers for certain types of plans.

A January report by nonprofit group KFF found that UnitedHealthcare denied 33% of in-network claims across Affordable Care Act plans in 20 states in 2023, one of the highest rates among major insurers. CVS denied 22% of claims across 11 states, and Cigna denied 21% in eight states.

UnitedHealth did not respond to a request for comment on that report. But in December, the company also pushed back on public criticism around its denial rates, saying it approves and pays about 90% of claims upon submission. UnitedHealthcare’s website says the remaining 10% go through an additional review process. The company says its claims approval rate stands at 98% after that review.

In addition, UnitedHealth Group is facing lawsuits over denials. In November, families of two deceased Medicare Advantage patients sued the company and its subsidiary, alleging it used an AI model with a “90% error rate” to deny their claims. UnitedHealth Group has argued it should be dismissed from the case because the families didn’t complete Medicare’s appeals process.

A spokesperson for the company’s subsidiary, NaviHealth, also previously told news outlets that the lawsuit “has no merit” and that the AI tool is used to help providers understand what care a patient may need. It does not help make coverage decisions, which are ultimately based on the terms of a member’s plan and criteria from the Centers for Medicare & Medicaid Services, the spokesperson said.

Meanwhile, the reported Justice Department criminal probe outlined by the Wall Street Journal targets the company’s Medicare Advantage business practices. In its statement, the company said the Justice Department has not notified it about the reported probe, and called the newspaper’s reporting “deeply irresponsible.”

Inside the company, employees say customers and workers alike face hurdles.

One worker, who requested anonymity for fear of retaliation, said UnitedHealthcare’s provider website often includes doctors listed as in-network or accepting new patients when they’re not, leading to frequent complaints. Management often replies that it’s too difficult to keep provider statuses up to date, the person said.

UnitedHealthcare told CNBC it believes “maintaining accurate provider directories is a shared responsibility among health plans and providers,” and that it “proactively verifies provider data on a regular basis.” The vast majority of all inaccuracies are due to errors or lack of up-to-date information submitted by providers, the company added.

Emily Baack, a clinical administrative coordinator at UMR, a subsidiary of UnitedHealthcare, criticized the length of time it can take a provider to reach a real support worker over the phone who can help assess claims or prior authorization requests. She said the company’s automated phone system can misroute people’s calls or leave them waiting for a support person for over an hour.

But Baack emphasized that similar issues occur across all insurance companies.

She said providers feel compelled to submit unnecessary prior authorization requests out of fear that claims won’t be paid on time. Baack said that leads to a massive backlog of paperwork on her end and delays care for patients.

UnitedHealthcare said prior authorization is “an important checkpoint” that helps ensure members are receiving coverage for safe and effective care.

The company noted it is “continually taking action to simplify and modernize the prior authorization process.” That includes reducing the number of services and procedures that require prior authorization and exempting qualified provider groups from needing to submit prior authorization requests for certain services.

While UnitedHealthcare is not the only insurer facing criticism from patients, Thompson’s killing in December reinforced the company’s unique position in the public eye. Thousands of people took to social media to express outrage toward the company, sharing examples of their own struggles.

The public’s hostile reaction to Thompson’s death did not surprise many industry insiders.

Alicia Graham, co-founder and chief operating officer of the startup Claimable, said Thompson’s murder was “a horrible crime.” She also acknowledged that anger has been bubbling up in various online health communities “for years.”

Claimable is one of several startups trying to address pain points within insurance. It’s not an easy corner of the market to enter, and many of these companies, including Claimable, have been using the AI boom to their advantage.

Claimable, founded in 2024, said it helps patients challenge denials by submitting customized, AI-generated appeal letters on their behalf. The company can submit appeals for conditions such as migraines and certain pediatric and autoimmune diseases, though Graham said it is expanding those offerings quickly.

Many patients aren’t aware that they have a right to appeal, and those who do can spend hours combing through records to draft one, Graham said. If patients are eligible to submit an appeal letter through Claimable, she said they can often do so in minutes. Each appeal costs users $39.95 plus shipping, according to the company’s website.

“A lot of patients are afraid, a lot of patients are frustrated, a lot of patients are confused about the process, so what we’ve tried to do is make it all as easy as possible,” Graham told CNBC.

Some experts have warned about the possibility of health-care “bot wars,” where all parties are using AI to try to gain an edge.

Mike Desjadon, CEO of the startup Anomaly, said he’s concerned about the potential for an AI arms race in the sector, but he remains optimistic. Anomaly, founded in 2020, uses AI to help providers determine what insurers are and aren’t paying for in advance of care, he said.

“I run a technology company and I want to win, and I want our customers to win, and that’s all very true, but at the same time, I’m a citizen and a patient and a husband and a father and a taxpayer, and I just want health care to be rational and be paid for appropriately,” Desjadon told CNBC.

Dr. Jeremy Friese, founder and CEO of the startup Humata Health, said patients tend to interact with insurers only once something goes wrong, which contributes to their frustrations. Requirements such as prior authorization can be a “huge black box” for patients, but they’re also cumbersome for doctors, he said.

Friese said his business was inspired by his work as an interventional radiologist. In 2017, he co-founded a prior-authorization company called Verata Health, which was acquired by the now-defunct health-care AI startup Olive. Friese bought back his technology and founded his latest venture, Humata, in 2023.

Humata uses AI to automate prior authorization for all specialties and payers, Friese said. The company primarily works with medium and large health systems, and it announced a $25 million funding round in June.

“There’s just a lot of pent-up anger and angst, frankly, on all aspects of the health-care ecosystem,” Friese told CNBC.

UnitedHealth Group also set a grim record last year that did little to help public perception. The company’s subsidiary Change Healthcare suffered a cyberattack that affected around 190 million Americans, the largest reported health-care data breach in U.S. history.

Change Healthcare offers payment and revenue cycle management tools, as well as other solutions, such as electronic prescription software. In 2022, it merged with UnitedHealth Group’s Optum unit, which touches more than 100 million patients in the U.S.

In February 2024, a ransomware group called Blackcat breached part of Change Healthcare’s information technology network. UnitedHealth Group isolated and disconnected the affected systems “immediately upon detection” of the threat, according to a filing with the U.S. Securities and Exchange Commission, but the ensuing disruption rocked the health-care sector.

Money stopped flowing while the company’s systems were offline, so a major revenue source for thousands of providers across the U.S. screeched to a halt. Some doctors pulled thousands of dollars out of their personal savings to keep their practices afloat.

“It was and remains the largest and most consequential cyberattack against health care in history,” John Riggi, the national advisor for cybersecurity and risk at the American Hospital Association, told CNBC.

Ransomware is a type of malicious software that blocks victims from accessing their computer files, systems and networks, according to the Federal Bureau of Investigation. Ransomware groups such as Blackcat, which are often based in countries such as Russia, China and North Korea, will deploy this software, steal sensitive data and then demand a payment for its return.

Ransomware attacks within the health-care sector have climbed in recent years, in part because patient data is valuable and relatively easy for cybercriminals to exploit, said Steve Cagle, CEO of the health-care cybersecurity and compliance firm Clearwater.

“It’s been a very lucrative and successful business for them,” Cagle told CNBC. “Unfortunately, we’ll continue to see that type of activity until something changes.”

UnitedHealth Group paid the hackers a $22 million ransom to try to protect patients’ data, then-CEO Witty said during a Senate hearing in May 2024.

In March 2024, UnitedHealth Group launched a temporary funding assistance program to help providers with short-term cash flow.

The program got off to a rocky start, several doctors told CNBC, and the initial deposits did not cover their mounting expenses.

UnitedHealth Group ultimately paid out more than $9 billion to providers in 2024, according to the company’s fourth-quarter earnings report in January.

Witty said in his congressional testimony that providers would only be required to repay the loans when “they, not me, but they confirm that their cash flow is normalized.”

Almost a year later, however, the company is aggressively going after borrowers, demanding they “immediately repay” their outstanding balances, according to documents viewed by CNBC and providers who received funding. Some groups have been asked to repay hundreds of thousands of dollars in a matter of days, according to documents viewed by CNBC.

A spokesperson for Change Healthcare confirmed to CNBC in April that the company has started recouping the loans.

We continue to work with providers on repayment and other options, and continue to reach out to those providers that have not been responsive to previous calls or email requests for more information,” the spokesperson said.

The pressure for repayment drew more ire toward UnitedHealth Group on social media, and some providers told CNBC that dealing with the company was a “very frustrating experience.”

The vast majority of Change Healthcare’s services have been restored over the last year, but three products are still listed as “partial service available,” according to UnitedHealth’s cyberattack response website.

Witty’s departure and the company’s warning about elevated medical costs, combined with the fallout from Thompson’s murder and the Change Healthcare cyberattack, could mean UnitedHealth faces an uphill battle.

UnitedHealth Group appears to be trying to regain the public’s trust. For example, Optum Rx in March announced plans to eliminate prior authorizations on dozens of drugs, easing a pain point for physicians and patients.

But policy changes at UnitedHealth Group and other insurers may not drastically improve care for patients, health insurance industry experts previously told CNBC.

They said there will need to be structural changes to the entire insurance industry, which will require legislation that may not be high on the priority list for the closely divided Congress.

The spotlight on UnitedHealth Group may only grow brighter in the coming months. The trial date for Luigi Mangione, the man facing federal stalking and murder charges in connection with Thompson’s shooting, is expected to be set in December. Mangione has pleaded not guilty to the charges.

This post appeared first on NBC NEWS

The Federal Trade Commission voted to dismiss a lawsuit filed in the last days of the Biden administration that accused PepsiCo of offering sweetheart pricing to big retailers.

FTC Chair Andrew Ferguson dissented to the suit when it was filed in January, when he was one of the regulator’s commissioners. Now the agency’s leader, Ferguson on Thursday again criticized the case as “a nakedly political effort to commit this administration to pursuing little more than a hunch that Pepsi had violated the law.”

“The FTC’s outstanding staff will instead get back to work protecting consumers and ensuring a fair and competitive business environment,” he said in a statement.

The FTC voted 3-0 to drop the suit. The panel is supposed to be made up of five commissioners, no more than three of whom can share the same political party. But it is currently led by three Republicans after President Donald Trump fired its two Democratic commissioners in March. The two ousted officials have slammed their removals as illegal and are urging a judge to reinstate them.

Pepsi welcomed the FTC decision Thursday. “PepsiCo has always and will continue to provide all customers with fair, competitive, and non-discriminatory pricing, discounts and promotional value,” a spokesperson said in a statement. Beyond its namesake soda, the company makes an array of snacks and other food products, including Doritos, Rold Gold pretzels and Sabra hummus.

Former FTC Chair Lina Khan, who led the commission when the agency brought its case against Pepsi, criticized the move Thursday as “disturbing behavior” by the agency.

“This lawsuit would’ve protected families from paying higher prices at the grocery store and stopped conduct that squeezes small businesses and communities across America,” she wrote on X Thursday evening. “Dismissing it is a gift to giant retailers as they gear up to hike prices.”

The decision comes little more than a week after top-ranking Democrats on Capitol Hill sent a letter to Pepsi demanding more information about its pricing strategy. They sought to revive a Biden-era focus on price-gouging as a driver of inflation, an argument that has taken a back seat to the Trump administration’s attention on purportedly unfair trade arrangements.

But major corporations continue to draw scrutiny from the White House over pricing in other ways. Last weekend, Trump slammed Walmart for warning that it was likely to raise prices to offset the costs of his import taxes, demanding on social media that it “EAT THE TARIFFS.”

In the days since then, other major consumer brands have appeared to tread cautiously around pricing. Target said Wednesday that charging customers more would be its “very last resort.” Home Depot virtually ruled out price hikes this week, and Lowe’s barely mentioned tariff impacts in its Wednesday earnings call at all.

CORRECTION (May 22, 2025, 8:45 p.m. ET): Due to an editing error, a previous version of this article misstated when congressional Democrats sent their letter to Pepsi. It was on May 11, not last weekend.

This post appeared first on NBC NEWS

President Donald Trump’s ‘one big, beautiful bill’ passed the House of Representatives early on Thursday morning with few Republican defections.

It is a significant victory for House Speaker Mike Johnson, R-La., who navigated deep inter-party friction within the House GOP Conference to deliver a product from which few Republican lawmakers ultimately defected.

The bill is a sweeping multi-trillion-dollar piece of legislation that advances Trump’s agenda on taxes, immigration, energy, defense and the national debt. It’s sought to make a dent in the federal government’s spending trajectory by cutting roughly $1.5 trillion in government spending elsewhere. The U.S. government is over $36 trillion in debt and has spent $1.05 trillion more than it’s collected in the 2025 fiscal year, according to the Treasury Department.

The bill passed 215 to 214 with just two Republicans, Reps. Thomas Massie, R-Ky., and Warren Davidson, R-Ohio, voting against it. All Democrats voted against the bill as well, and House Freedom Caucus Chair Andy Harris, R-Md., voted ‘present.’

Republicans spent more than 48 hours continuously working on the bill from the time it came before the House Rules Committee – the final gatekeeper before a House-wide vote – at 1 a.m. on Wednesday to when it passed the chamber just after 7 a.m. on Thursday.

‘It quite literally is morning again in America,’ Johnson said. ‘What we’re achieving today is nothing short of historic.’

All the while, Democratic lawmakers attempted a variety of delay tactics, from introducing amendments targeting key Trump policies to forcing several procedural votes on the House floor ahead of debate on the legislation.

House Minority Leader Hakeem Jeffries, D-N.Y., notably spoke on the House floor for over 30 minutes just before the vote in a last-ditch effort to stretch out the seemingly endless day of debate and votes.

‘This bill represents a failed promise. Last year, Donald Trump and House Republicans spent all of their time to lower the high cost of living in the United States of America,’ Jeffries said on the House floor. ‘We’re now more than 120 days past the inauguration. Costs aren’t going down, they’re going up.’ 

Tensions flared at multiple points as visibly weary lawmakers continued to fight their ideological battle into the early morning. 

Rep. Steve Womack, R-Ark., who was presiding over the House at the time, warned Jeffries multiple times to address the chair in his remarks rather than directly attacking Republicans sitting across the chamber.

‘Every time I’m interrupted, that’s going to add another 15 minutes to my remarks,’ Jeffries said as Democrats sitting around him sounded off in support.

The bill seeks to permanently extend Trump’s 2017 Tax Cuts and Jobs Act (TCJA) while also implementing newer Trump campaign promises like eliminating taxes on tips and overtime pay, and giving senior citizens a higher tax deduction for a period of four years.

The legislation also included new funding for the border and defense, including more money for Immigration and Customs Enforcement (ICE) operations and $25 billion to kick-start construction of a ‘Golden Dome’ defense system over the U.S.

Cuts include new work requirements for able-bodied Medicaid recipients, as well as putting more of the cost-sharing burden on states that took advantage of the Affordable Care Act (ACA)’s expanded Medicaid enrollment by giving illegal immigrants access to the healthcare program.

The legislation would also roll back a host of green energy tax credits awarded in former President Joe Biden’s Inflation Reduction Act (IRA) – which Trump vowed to repeal in its entirety on the campaign trail. 

It also would cut the Supplemental Nutrition Assistance Program (SNAP) by roughly 20% by introducing some cost-sharing burdens on the states and increasing the amount of able-bodied Americans facing work requirements to be eligible for food stamps.

All House Democrats rejected the bill, accusing Republicans of disproportionately favoring the wealthy at the expense of critical programs for working Americans. Republicans, on the other hand, have contended that they are preserving tax cuts that prevent a 22% tax increase on Americans next year if TCJA was allowed to expire, as well as streamlining programs like Medicaid and SNAP for vulnerable Americans who need it most.

Rep. August Pfluger, R-Texas, chair of the House’s 189 member-strong Republican Study Committee, told Fox News Digital, ‘This transformational legislation permanently extends President Trump’s historic tax cuts, provides unprecedented funding for border security, and obliterates the last four years of catastrophic Democratic policies.’

And while most GOP lawmakers united on the final bill, divisions appeared to persist until the final moments. Conservatives had pushed for more aggressive targeting of Medicaid waste and Biden green energy subsidies, while blue state Republicans pushed for tax relief for Americans in high-cost-of-living areas. 

To resolve outstanding differences, House Republican leaders released a list of eleventh-hour changes to President Donald Trump’s ‘one big, beautiful bill,’ hours before their full chamber is expected to consider the legislation.

New provisions in the bill include a ban on federal funding for transgender adults’ medical care, and $12 billion in new funding to reimburse states for money they spent countering the former Biden administration’s border policies. 

A key request from fiscal conservatives was also honored, with House GOP leaders apparently agreeing to speed up the implementation of work requirements for certain able-bodied recipients of Medicaid.

The bill initially had Medicaid work requirements going into effect in 2029.

Rep. Chip Roy, R-Texas, one of the fiscal hawks leading GOP opposition to the bill, told Fox News Digital just after midnight Thursday that he was not sure if the legislation went far enough – but suggested the White House could persuade him with other avenues for change.

‘There are things in the executive space, executive actions that we think could take care of … some of our concerns on the Medicaid expansion,’ Roy said.

The legislative update also included a victory for blue state Republicans who have been pushing for a higher state and local tax (SALT) deduction cap – the current $10,000 cap would be quadrupled to roughly $40,000, but only for people making less than $500,000 per year. The $10,000 cap was first instituted in TCJA. 

‘This is what real leadership looks like. President Trump and House Republicans made a promise to the American people to secure our border, protect seniors, cut taxes on tips and overtime, and shut off the spigot of benefits for illegal immigrants,’ first-term Rep. Mike Haridopolos, R-Fla., told Fox News Digital. 

Rep. Randy Feenstra, R-Iowa, told Fox News Digital, ‘More than 77 million Americans made clear at the polls that they want President Trump’s America First agenda codified into law, and our ‘One, Big, Beautiful Bill’ delivers on this promise.’

But while House GOP leaders are enjoying their hard-fought victory now, the battle over Trump’s ‘big, beautiful bill’ is not over.

Senate Republicans have already signaled they expect to make changes to the bill when it reaches the upper chamber, despite House GOP leaders publicly urging them to amend as little as possible.

There is a significant number of senators who have expressed wariness at the level of Medicaid and SNAP cuts sought by the House. An increase to the SALT deduction cap could also be met with skepticism in the Senate, where no Republican represents a blue state – unlike the House, where New York and California districts are critical to the majority.

The House and Senate must pass identical bills before sending them to Trump’s desk for a signature. GOP leaders have signaled they hope to do that by the Fourth of July.

This post appeared first on FOX NEWS